Anti-inflammatory properties and regulatory mechanism of a novel derivative of artemisinin in experimental autoimmune encephalomyelitis

Journal of Immunology

Volumn 179, Issue 9, 2007, Pages 5958-5965

  Wang, Zhaojun ^a   Qiu, Ju ^a   Guo, Taylor B ^a   Liu, Ailian ^a   Wang, Ying ^a   Li, Yin ^b   Zhang, Jingwu Z ^a,c  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^c University of Shanghai   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ARTEMISIN DERIVATIVE; CYCLIN A; CYCLIN DEPENDENT KINASE 2; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ETHYL 2 [4 (12 BETA ARTEMISININOXY)]PHENOXYLPROPIONATE; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; PROTEIN JAB1; REGULATOR PROTEIN; RIG G PROTEIN; SM 933; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR T BET; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; ARTEMISININ DERIVATIVE; AUTACOID; ETHYL 2 (4 (12 BETA ARTEMISININOXY))PHENOXYLPROPIONATE; ETHYL 2-(4-(12-BETA-ARTEMISININOXY))PHENOXYLPROPIONATE;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL DESTRUCTION; CELL NUCLEUS; CELL TRANSPORT; CELLULAR DISTRIBUTION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DOWN REGULATION; DOWNSTREAM PROCESSING; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; EX VIVO STUDY; IMMUNOREGULATION; INTERFERON PRODUCTION; LD 50; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SPLEEN CELL; TH1 CELL; TH2 CELL; UPREGULATION; ANIMAL; C57BL MOUSE; CELL CULTURE; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMICALLY INDUCED DISORDER; CHEMISTRY; CYTOLOGY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PATHOLOGY; SPLEEN; T LYMPHOCYTE;

ANIMALS; ARTEMISININS; CELL PROLIFERATION; CELLS, CULTURED; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; INFLAMMATION MEDIATORS; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED C57BL; MOLECULAR STRUCTURE; NF-KAPPA B; SPLEEN; T-LYMPHOCYTES;

EID: 38449100734     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.179.9.5958     Document Type: Article

References (35)

1. Hafler, D. A. 2004. Multiple sclerosis. J. Clin. Invest. 113: 788-794.
2. Skapenko, A., P. E. Lipsky, and H. Schulze-Koops. 2006. T cell activation as starter and motor of rheumatic inflammation. Curr. Top. Microbiol. Immunol. 305: 195-211.
3. Prat, A., and J. Antel. 2005. Pathogenesis of multiple sclerosis. Curr. Opin. Neurol. 18: 225-230.
4. + cytotoxic T cell responses to myelin basic protein in multiple sclerosis. J. Immunol. 172: 5120-5127.
5. Bornstein, M. B., A. Miller, S. Slagle, M. Weitzman, H. Crystal, E. Drexler, M. Keilson, A. Merriam, S. Wassertheil-Smoller, V. Spada, et al. 1987. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N. Engl. J. Med. 317: 408-414.
6. Rizvi, S. A., and M. A. Agius. 2004. Current approved options for treating patients with multiple sclerosis. Neurology 63: S8-S14.
7. Jeffery, D. R. 2004. Use of combination therapy with immunomodulators and immunosuppressants in treating multiple sclerosis. Neurology 63: S41-S46.
8. Gran, B., L. R. Tranquill, M. Chen, B. Bielekova, W. Zhou, S. Dhib-Jalbut, and R. Martin. 2000. Mechanisms of immunomodulation by glatiramer acetate. Neurology 55: 1704-1714.
9. Di Carlo, G., F. Borrelli, E. Ernst, and A. A. Izzo. 2001. St. John's wort: prozac from the plant kingdom. Trends Pharmacol. Sci. 22: 292-297.
10. Zhang, H. Y., and X. C. Tang. 2006. Neuroprotective effects of huperzine A: new therapeutic targets for neurodegenerative disease. Trends Pharmacol. Sci. 27: 619-625.
11. Breman, J. G., M. S. Alilio, and A. Mills. 2004. Conquering the intolerable burden of malaria: what's new, what's needed: a summary. Am. J. Trop. Med. Hyg. 71: 1-15.
12. White, N. J. 2004. Antimalarial drug resistance. J. Clin. Invest. 113: 1084-1092.
13. Golenser, J., J. H. Waknine, M. Krugliak, N. H. Hunt, and G. E. Grau. 2006. Current perspectives on the mechanism of action of artemisinins. Int. J. Parasitol. 36: 1427-1441.
14. Zhang, J., and C. L. Yang. 2005. Pharmacology and toxicology of artemisinins. J. Hebei NU 22: 75-77.
15. Yang, Z. S., W. L. Zhou, Y. Sui, J. X. Wang, J. M. Wu, Y. Zhou, Y. Zhang, P. L. He, J. Y. Han, W. Tang, et al. 2005. Synthesis and immunosuppressive activity of new artemisinin derivatives, 1: [12(β or α)- dihydroartemisininoxy] phen(ox)yl aliphatic acids and esters. J. Med. Chem. 48: 4608-4617.
16. Furlan, R., E. Brambilla, F. Ruffini, P. L. Poliani, A. Bergami, P. C. Marconi, D. M. Franciotta, G. Penna, G. Comi, L. Adorini, and G. Martino. 2001. Intrathecal delivery of IFN-γ protects C57BL/6 mice from chronic-progressive experimental autoimmune encephalomyelitis by increasing apoptosis of central nervous system-infiltrating lymphocytes. J. Immunol. 167: 1821-1829.
17. Zhang, J., R. Medaer, P. Stinissen, D. Hafler, and J. Raus. 1993. MHC-restricted depletion of human myelin basic protein-reactive T cells by T cell vaccination. Science 261: 1451-1454.
18. Zhang, J., S. Markovic-Plese, B. Lacet, J. Raus, H. L. Weiner, and D. A. Hafler. 1994. Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J. Exp. Med. 179: 973-984.
19. Li, F., Y. Mei, Y. Wang, C. Chen, J. Tu, B. Xiao, and L. Xu. 2005. Trichosanthin inhibits antigen-specific T cell expansion through nitric oxide-mediated apoptosis pathway. Cell. Immunol. 234: 23-30.
20. Green, L. C., D. A. Wagner, J. Glogowski, P. L. Skipper, J. S. Wishnok, and S. R. Tannenbaum. 1982. Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal. Biochem. 126: 131-138.
21. Nagaki, M., T. Naiki, D. A. Brenner, Y. Osawa, M. Imose, H. Hayashi, Y. Banno, S. Nakashima, and H. Moriwaki. 2000. Tumor necrosis factor α prevents tumor necrosis factor receptor-mediated mouse hepatocyte apoptosis, but not fas-mediated apoptosis: role of nuclear factor-κB. Hepatology 32: 1272-1279.
22. Van Loo, G., R. De Lorenzi, H. Schmidt, M. Huth, A. Mildner, M. Schmidt-Supprian, H. Lassmann, M. R. Prinz, and M. Pasparakis. 2006. Inhibition of transcription factor NF-κB in the central nervous system ameliorates autoimmune encephalomyelitis in mice. Nat. Immunol. 7: 954-961.
23. Hilliard, B., E. B. Samoilova, T. S. Liu, A. Rostami, and Y. Chen. 1999. Experimental autoimmune encephalomyelitis in NF-κB-deficient mice: roles of NF-κB in the activation and differentiation of autoreactive T cells. J. Immunol. 163: 2937-2943.
24. Mattson, M. P., and S. Camandola. 2001. NF-κB in neuronal plasticity and neurodegenerative disorders. J. Clin. Invest. 107: 247-254.
25. Barnes, P. J., and M. Karin. 1997. Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med. 336: 1066-1071.
26. Goudeau, B., F. Huetz, S. Samson, J. P. Di Santo, A. Cumano, A. Beg, A. Israel, and S. Memet. 2003. IκBα/IκBε deficiency reveals that a critical NF-κB dosage is required for lymphocyte survival. Proc. Natl. Acad. Sci. USA 100: 15800 -15805.
27. Jimi, E., and S. Ghosh. 2005. Role of nuclear factor-κB in the immune system and bone. Immunol. Rev. 208: 80-87.
28. Aktas, O., T. Prozorovski, A. Smorodchenko, N. E. Savaskan, R. Lauster, P. M. Kloetzel, C. Infante-Duarte, S. Brocke, and F. Zipp. 2004. Green tea epigallocatechin-3-gallate mediates T cellular NF-κB inhibition and exerts neuroprotection in autoimmune encephalomyelitis. J. Immunol. 173: 5794-5800.
29. MacMicking, J., Q. W. Xie, and C. Nathan. 1997. Nitric oxide and macrophage function. Annu. Rev. Immunol. 15: 323-350.
30. Xiao, S., D. Li, H. Q. Zhu, M. G. Song, X. R. Pan, P. M. Jia, L. L. Peng, A. X. Dou, G. Q. Chen, S. J. Chen, et al. 2006. RIG-G as a key mediator of the antiproliferative activity of interferon-related pathways through enhancing p21 and p27 proteins. Proc. Natl. Acad. Sci. USA 103: 16448-16453.
31. Ann Marrie, R., and R. A. Rudick. 2006. Drug insight: interferon treatment in multiple sclerosis. Nat. Clin. Pract. Neurol. 2: 34-44.
32. Farina, C., M. S. Weber, E. Meinl, H. Wekerle, and R. Hohlfeld. 2005. Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action. Lancet Neurol. 4: 567-575.
33. Lyss, G., A. Knorre, T. J. Schmidt, H. L. Pahl, and I. Merfort. 1998. The antiinflammatory sesquiterpene lactone helenalin inhibits the transcription factor NF-κB by directly targeting p65. J. Biol. Chem. 273: 33508-33516.
34. Garcia-Pineres, A. J., V. Castro, G. Mora, J. Schmidt, E. Strunck, H. L. Pahl, and I. Merfort. 2001. Cysteine 38 in p65/NF-κB plays a crucial role in DNA binding inhibition by sesquiterpene lactones. J. Biol. Chem. 276: 39713-39720.
35. Hehner, S. P., M. Heinrich, P. M. Bork, M. Vogt, F. Ratter, V. Lehmann, K. Schulze-Osthoff, W. Droge, and M. L. Schmitz. 1998. Sesquiterpene lactones specifically inhibit activation of NF-κB by preventing the degradation of IκB-α and IκB-β. J. Biol. Chem. 273: 1288-1297.